*Credentials required. Check your site's credentialing status.*

Quality of Life substudy (70702) is closed. (effective 8/30/17)
CURRENT SITES CREDENTIALED:
Oakland, SJMH, Livonia, Saginaw, St. John, Macomb, St. Alphonsus, Genesys, Lehigh, Sparrow

-Histologically or cytologically confirmed small cell lung cancer
-Limited-stage disease
-Disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes
-Patients with cytologically positive pleural or pericardial fluid are NOT eligible
-Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are NOT eligible
-Patients must have measurable disease
-Patients may have received one and only one cycle of chemotherapy prior to enrollment, which must have included carboplatin or cisplatin or etoposide
-No prior radiotherapy 
-Patients with complete surgical resection of disease are NOT eligible
-ECOG PS 0-2

Open to Ann Arbor, Brighton, Canton, Chelsea, and Livonia. 

Inclusion Criteria:

• Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy
• Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as detected by food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory in accordance with site standard of care
• Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated
• Any toxicities from prior systemic anticancer therapy must have resolved to national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or baseline level (except for alopecia [any grade], grade <=2 peripheral neuropathy, or grade <=2 hypothyroidism stable on hormone replacement)
• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion Criteria:

• Medical history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
• Had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before the first dose of anticancer treatments or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
• Participant has uncontrolled tumor-related pain (symptomatic lesions amenable to palliative radiotherapy should be treated prior to first dosing)
• Received an investigational treatment that has not been cleared (based on at least 5 half lives of any pharmaceutical treatment) or within 12 months before the planned first dose of study treatment or is currently enrolled in an investigational study
• Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)

-Histologically confirmed adenocarcinoma of the prostate
-No small cell, neuroendocrine, or transitional cell carcinoma
-Clinically localized, stage T1-3a disease
-No radiographic evidence of metastatic disease
-Serum prostate-specific antigen level = 100 ng/mL within the past 6 weeks
-Patients must have high-risk disease determined by EITHER--
--Probability of biochemical progression-free survival at 5 years after surgery 60% by Kattan nomogram prediction or
--Prostate biopsy gleason sum greater than or equal to 8
-Patients must be deemed an appropriate candidate for radical prostatectomy
-No prior treatment for prostate cancer, including surgery, pelvic lymph node dissection, radiotherapy, or chemotherapy
-ECOG performance status 0-2